Medeva Changes Tack
Criticized for not properly managing growth, Medeva's managers contend they're building a sustainable business. They used profits from methylphenidate, an off-patent treatment for attention deficit disorder, to finance a long list of acquisitions, many of which didn't work out. When methylphenidate sales crashed with the entrance of generic competition, so did Medeva's credibility with investors. They're hoping their self-sustaining European and American infrastructure will help them attract the higher-risk, higher profit products they shunned in their original strategy but now need in order to dig themselves out of their profit hole.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.